MedPath

Nomacopan

Generic Name
Nomacopan
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
875125-19-2
Unique Ingredient Identifier
79V7Q9VIWQ
Background

Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).

Associated Conditions
-
Associated Therapies
-
clarivate.com
·

Bullous Pemphigoid - Executive Insights - Bullous Pemphigoid

Bullous pemphigoid (BP) affects elderly patients, often misdiagnosed, with no approved therapies in the US. Current treatments include off-label corticosteroids and immunomodulators. The BP pipeline includes advanced Phase III therapies like AstraZeneca’s Fasenra, Sanofi/Regeneron’s Dupixent, and Akari Therapeutics’ nomacopan. Unmet needs and market opportunities are significant due to lack of approved therapies and diagnostic biomarkers.
© Copyright 2025. All Rights Reserved by MedPath